Site-specific chemical modification of recombinant proteins produced in mammalian cells by using the genetically encoded aldehyde tag

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 9, 2009, Pages 3000-3005

  Wu, Peng ^a   Shui, Wenqing ^a   Carlson, Brian L ^a   Hu, Nancy ^a   Rabuka, David ^a   Lee, Julia ^a   Bertozzi, Carolyn R ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

Author keywords

Antibody engineering; Bioorthogonal reaction

Indexed keywords

CELL SURFACE PROTEIN; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANTIBODY ENGINEERING; ARTICLE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PROCESSING;

ALDEHYDES; AMINO ACID SEQUENCE; ANIMALS; CELL LINE; CELL MEMBRANE; CRICETINAE; HUMANS; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS;

MAMMALIA;

EID: 62549121136     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0807820106     Document Type: Article

References (27)

1. Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: A summary and pharmacological classification. Nat Rev Drug Discovery 7:21-39.
2. Waldmann TA (2003) Immunotherapy: Past, present and future. Nat Med 9:269-277.
3. Kochendoerfer GG (2005) Site-specific polymer modification of therapeutic proteins. Curr Opin Chem Biol 9:555-560.
4. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discovery 2:214-221.
5. Wu AM, Senter PD (2005) Arming antibodies: Prospects and challenges for immunoconjugates. Nat Biotechnol 23:1137-1146.
6. Junutula JR, et al. (2008) Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 26:925-932.
7. Griffin BA, Adams SR, Tsien RY (1998) Specific covalent labeling of recombinant protein molecules inside live cells. Science 281:269-272.
8. Prescher JA, Bertozzi, CR (2005) Chemistry in living systems. Nat Chem Biol 1:13-21.
9. Gilmore JM, Scheck RA, Esser-Kahn AP, Joshi NS, Francis MB (2006) N-terminal protein modification through a biomimetic transamination reaction. Angew Chem Int Ed 45:5307-5311.
10. Wang L, Schultz PG (2004) Expanding the genetic code. Angew Chem Int Ed 44:34-66.
11. Chen I, Howarth M, Lin W, Ting AY (2005) Site-specific labeling of cell surface proteins with biophysical probes using biotin ligase. Nat Meth 2:99-104.
12. Yin J, et al. (2005) Genetically encoded short peptide tag for versatile protein labeling by Sfp phosphopantetheinyl transferase. Proc Natl Acad Sci USA 102:15815-15820.
13. Fernandez-Suarez M, et al. (2007) Redirecting lipoic acid ligase for cell surface protein labeling with small-molecule probes. Nat Biotechnol 25:1483-1487.
14. Dierks T, et al. (2003) Multiple sulfatase deficiency is caused by mutations in the gene encoding the human C-alpha-formylglycine generating enzyme. Cell 113:435-444.
15. Hanson SR, Best MD, Wong CH (2004) Sulfatases: Structure, mechanism, biological activity, inhibition, and synthetic utility. Angew Chem Int Ed 43:5736-5763.
16. Carrico IS, Carlson BL, Bertozzi CR (2007) Introducing genetically encoded aldehydes into proteins. Nat Chem Biol 3:321-322.
17. Jenkins N, Murphy L, Tyther R (2008) Post-translational modifications of recombinant proteins: Significance for Biopharmaceuticals. Mol Biotechnol 39:113-118.
18. Kaneko Y, Nimmerjahn F,(2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670-673.
19. Anthony RM, et al. (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320:373-376.
20. Dumont JA, Low SC, Peters RT, Bitonti AJ (2006) Monomeric Fc fusions: Impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 20:151-160.
21. Gobom J, et al. (2000) Detection and quantification of neurotensin in human brain tissue by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Anal Chem 72:3320-3326.
22. Hofer T, et al. (2007) Chimeric rabbit/human Fab and IgG specific for members of the Nogo-66 receptor family selected for species cross-reactivity with an improved phage display vector. J Immunol Meth 318:75-87.
23. Rader C, Popkov M, Neves JA, Barbas CF, III (2002) Integrin alpha(v) beta3 targeted therapy for Kaposi's sarcoma with an in vitro evolved antibody. FASEB J 16:2000-2002.
24. O'Garra A, Murphy K (1993) T-cell subsets in autoimmunity. Curr Opin Immunol 5:880-886.
25. Carlson BL, et al. (2008) Function and structure of a prokaryotic formylglycine-generating enzyme. J Biol Chem 283:20117-20125.
26. Landgrebe J, Dierks T, Schmidt B, Von Figura K (2003) The human SUMF1 gene, required for posttranslational sulfatase modification, defines a new gene family which is conserved from pro- to eukaryotes. Gene 316:47-56.
27. Kiick KL, Saxon E, Tirrell DA, Bertozzi CR (2002) Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation. Proc Natl Acad Sci USA 99:19-24.